In particular, higher ERBB2 incidence and CN gains were observed in GC and CRC patients in the absence of other oncogenic alterations, indicating that HER2 may be the dominant driver of tumor proliferation in those settings. This evidence concerns the gene ERBB2 and gastric cancer.